{"title":"抗转移药物,药理学的挑战与机遇","authors":"D. Lu, Ting-Ren Lu","doi":"10.2174/0115748855284405231212051251","DOIUrl":null,"url":null,"abstract":"\n\nCancer is a complex and high-mortality disease in the clinic. Cancer metastasis leads to\nmost cancer deaths. The therapeutics for cancer metastasis are greatly unsatisfactory now. Despite\ndifferent types of antimetastatic agents and drugs have been reported, 90% of patients die in 5 years\nafter metastatic nodules at secondary sites have been found.\n\n\n\nMany pharmacologic challenges and opportunities for current metastasis therapies are presented. To\novercome the dilemma and shortcomings of antimetastatic treatment, medical, chemical, pharmaceutical,\nmethodological and technical issues are integrated and highlighted. To introduce up-to-date\nknowledge and insights into drug targeting and pharmaceutical features and clinical paradigms, relevant\ndrug design insights are discussed—including different pathological modes, diagnosis advances,\nmetastatic cascade, tumor plasticity, variety of animal models, therapeutic biomarkers, computational\ntools and cancer genomics. Integrated knowledge, systems and therapeutics are focused.\n\n\n\nIn summary, medicinal comparison, pharmaceutical innovation and clinical strategies should be increasingly\ninvestigated.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antimetastatic Drug, Pharmacologic Challenge and Opportunity\",\"authors\":\"D. Lu, Ting-Ren Lu\",\"doi\":\"10.2174/0115748855284405231212051251\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nCancer is a complex and high-mortality disease in the clinic. Cancer metastasis leads to\\nmost cancer deaths. The therapeutics for cancer metastasis are greatly unsatisfactory now. Despite\\ndifferent types of antimetastatic agents and drugs have been reported, 90% of patients die in 5 years\\nafter metastatic nodules at secondary sites have been found.\\n\\n\\n\\nMany pharmacologic challenges and opportunities for current metastasis therapies are presented. To\\novercome the dilemma and shortcomings of antimetastatic treatment, medical, chemical, pharmaceutical,\\nmethodological and technical issues are integrated and highlighted. To introduce up-to-date\\nknowledge and insights into drug targeting and pharmaceutical features and clinical paradigms, relevant\\ndrug design insights are discussed—including different pathological modes, diagnosis advances,\\nmetastatic cascade, tumor plasticity, variety of animal models, therapeutic biomarkers, computational\\ntools and cancer genomics. Integrated knowledge, systems and therapeutics are focused.\\n\\n\\n\\nIn summary, medicinal comparison, pharmaceutical innovation and clinical strategies should be increasingly\\ninvestigated.\\n\",\"PeriodicalId\":11004,\"journal\":{\"name\":\"Current Drug Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2024-01-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Drug Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115748855284405231212051251\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748855284405231212051251","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Antimetastatic Drug, Pharmacologic Challenge and Opportunity
Cancer is a complex and high-mortality disease in the clinic. Cancer metastasis leads to
most cancer deaths. The therapeutics for cancer metastasis are greatly unsatisfactory now. Despite
different types of antimetastatic agents and drugs have been reported, 90% of patients die in 5 years
after metastatic nodules at secondary sites have been found.
Many pharmacologic challenges and opportunities for current metastasis therapies are presented. To
overcome the dilemma and shortcomings of antimetastatic treatment, medical, chemical, pharmaceutical,
methodological and technical issues are integrated and highlighted. To introduce up-to-date
knowledge and insights into drug targeting and pharmaceutical features and clinical paradigms, relevant
drug design insights are discussed—including different pathological modes, diagnosis advances,
metastatic cascade, tumor plasticity, variety of animal models, therapeutic biomarkers, computational
tools and cancer genomics. Integrated knowledge, systems and therapeutics are focused.
In summary, medicinal comparison, pharmaceutical innovation and clinical strategies should be increasingly
investigated.
期刊介绍:
Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.